Spend {{difference_amount}} more and get 15% discount

Test

Sale!

CJC-1295 No DAC

Name: CJC-1295 No DAC
Brand: Peptide Titans
SKU: 522
Availability: InStock

Price range: $274.99 through $524.99

CJC-1295 (No DAC) is a synthetic growth hormone–releasing hormone (GHRH) analog studied for its ability to stimulate pulsatile growth hormone release by activating GHRH receptors. The “No DAC” version has a shorter half-life, resulting in more transient activity compared to DAC-modified forms. In research settings, it’s explored for effects on IGF-1 signaling, metabolism, and tissue-related pathways. Intended for research use only, not for human or veterinary use.

Clear

Molecular Characteristics

Complete Specifications

CAS Registry Number: Not assigned (modified GRF analog)
PubChem CID: Not available
Peptide Classification: Synthetic growth hormone–releasing factor (GRF 1–29) analog
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3,367.9 Da

Structural Composition

Amino Acid Sequence:
Modified 29-amino-acid GRF (1–29) sequence with substitutions at positions 2, 8, 15, and 27 to enhance stability
Length: 29 amino acids (modified)

Physical Properties

Appearance: White to off-white lyophilized powder
Solubility: Water, bacteriostatic water, phosphate-buffered saline (PBS)

Structural & Stability Notes

CJC-1295 (No DAC) is a modified 29-amino-acid peptide derived from growth hormone–releasing factor (GRF 1–29). Targeted amino acid substitutions enhance resistance to enzymatic degradation while preserving the core structural framework. Unlike DAC-conjugated versions, this variant does not include a drug affinity complex moiety, resulting in a shorter structural persistence profile under research conditions. Lyophilized presentation supports stability during storage, and protection from moisture, light, and repeated freeze–thaw cycles helps maintain peptide integrity for laboratory and analytical applications.

Research Applications

Growth Hormone Releasing Hormone (GHRH) Research

CJC-1295 (No DAC) is utilized as a research compound in studies examining growth hormone–releasing hormone (GHRH) receptor signaling and pulsatile endocrine regulation. Laboratory investigations focus on its role in:

GHRH Receptor Activation Models: Investigation of receptor binding dynamics and downstream signaling cascades
Pulsatile Growth Hormone Signaling: Evaluation of transient hormone release patterns under experimental conditions
cAMP Pathway Studies: Analysis of intracellular signaling mechanisms triggered by GHRH receptor engagement
Endocrine Feedback Loop Research: Examination of regulatory pathways influencing pituitary hormone dynamics
Short-Acting Peptide Kinetics: Investigation of receptor interaction duration and signaling half-life characteristics

Experimental protocols commonly employ receptor-binding assays, pituitary cell cultures, and hormone secretion models to characterize CJC-1295 (No DAC)–mediated signaling responses.

Endocrine and Metabolic Research

CJC-1295 (No DAC) has been extensively studied in research models examining endocrine regulation and metabolic signaling. Key areas of investigation include:

Insulin-Like Growth Factor (IGF) Signaling Models: Evaluation of downstream pathways associated with growth hormone–mediated signaling
Protein Synthesis Pathway Research: Investigation of intracellular signaling influencing anabolic processes
Lipid and Glucose Interaction Studies: Analysis of metabolic cross-regulation in response to endocrine signaling
Energy Utilization Models: Research into systemic energy balance under growth hormone modulation
Hormonal Pulse Pattern Analysis: Examination of physiological timing and amplitude of hormone release

This body of research utilizes endocrine profiling, metabolic assays, and longitudinal hormone monitoring systems to evaluate signaling outcomes.

Peptide Pharmacokinetics and Signal Duration Research

CJC-1295 (No DAC) is also examined in studies focused on short-acting peptide kinetics and receptor engagement duration, including:

Receptor Binding Affinity Studies: Evaluation of interaction strength with GHRH receptors
Signal Onset and Duration Models: Investigation of transient signaling characteristics compared to long-acting analogs
Peptide Stability Analysis: Research into degradation kinetics and plasma persistence under laboratory conditions
Comparative Signaling Profiles: Examination of receptor activation patterns relative to extended-duration analogs

Laboratory protocols assess pharmacokinetic characteristics, receptor occupancy, and signal attenuation using biochemical and analytical techniques.

Cellular Signaling and Growth Pathway Research

Additional research applications explore CJC-1295 (No DAC)’s influence on intracellular growth-related signaling systems, including:

MAPK and PI3K Pathway Studies: Investigation of downstream cascades associated with growth hormone signaling
Gene Expression Profiling: Analysis of transcriptional responses linked to endocrine modulation
Cellular Adaptation Mechanisms: Research into adaptive responses to pulsatile hormone signaling
Homeostatic Regulation Systems: Examination of feedback mechanisms preserving endocrine balance

Research in this domain focuses on understanding how CJC-1295 (No DAC) modulates GHRH receptor signaling, endocrine pulse patterns, and downstream growth-related pathways under controlled experimental conditions.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage

Store at –20°C to –80°C in the original, sealed vial
Protect from light exposure and moisture
A desiccated storage environment is recommended
Stability data suggests extended stability when stored at −20 °C or below.

Reconstitution Guidelines

Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol), or an appropriate laboratory buffer
Introduce solvent slowly along the vial wall to minimize foaming
Mix using gentle swirling; avoid vigorous agitation or shaking
Allow complete dissolution prior to use (typically 1–2 minutes)
Ensure the final solution is within a physiologically neutral pH range appropriate for laboratory use

Reconstituted Solution Storage

Short-term storage: Up to 7 days at 4°C
Long-term storage: Store at –20°C in aliquots
Use single-use aliquots to preserve peptide integrity
Minimize freeze–thaw cycles; single-use aliquots are strongly recommended

Stability Characteristics

CJC-1295 (No DAC) is a synthetic peptide research compound that demonstrates stable handling characteristics when managed according to standard peptide laboratory protocols. Proper cold storage of the lyophilized material, careful reconstitution, and minimized freeze–thaw exposure help preserve structural integrity and solubility. When handled appropriately, CJC-1295 (No DAC) supports consistent use in in vitro and analytical research applications.

Frequently Asked Questions

What is CJC-1295 (No DAC)?

CJC-1295 (No DAC) is a modified GHRH analog studied in laboratory settings for its ability to activate GHRH receptors and influence downstream growth hormone signaling pathways in preclinical research models.

What does “No DAC” mean?

“No DAC” indicates that the peptide does not include the Drug Affinity Complex modification that extends half-life in research models. As a result, CJC-1295 (No DAC) typically demonstrates a shorter duration of activity compared to CJC-1295 with DAC.

What is CJC-1295 (No DAC) commonly researched for?

In experimental research environments, it is studied for:

GHRH receptor activation
Growth hormone pulsatility models
IGF-1 pathway research
Endocrine signaling pathway investigation

All applications are exploratory and conducted in preclinical or laboratory settings.

How does CJC-1295 (No DAC) differ from CJC-1295 with DAC?

The primary difference is the presence of the Drug Affinity Complex (DAC) in the extended version. The DAC modification allows binding to serum albumin in research models, extending circulation time. The No DAC version lacks this modification and therefore has a shorter activity window in comparative studies.

How is CJC-1295 (No DAC) supplied?

CJC-1295 (No DAC) is typically supplied as a lyophilized (freeze-dried) powder in sealed research vials to maintain stability during storage and shipment.

How should unreconstituted CJC-1295 (No DAC) be stored?

Lyophilized peptide should be stored:

Long-term: −20 °C to −80 °C
Short-term: 2–8 °C

Keep vials sealed and protected from light and moisture.

How should reconstituted CJC-1295 (No DAC) be handled and stored?

Once reconstituted:

Store at 2–8 °C for short-term laboratory use
For longer-term storage, aliquot and freeze at −20 °C or below
Minimize freeze–thaw cycles using single-use aliquots
Gently swirl to mix; avoid vigorous agitation

Is CJC-1295 (No DAC) FDA-approved?

No. CJC-1295 (No DAC) is not FDA-approved as a drug, supplement, or therapeutic product. It is sold exclusively as a research compound and must not be marketed or used for diagnostic, therapeutic, or consumption purposes.

Does CJC-1295 (No DAC) require a Certificate of Analysis (COA)?

Yes. A Certificate of Analysis (COA) should be available for each batch, confirming peptide identity, purity, and analytical testing results to support research quality and traceability.

⚠️ Research Use Only

This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.

Any clinical data or research information referenced on this page is derived from peer-reviewed scientific literature and official publications. This information is provided for educational reference only and does not constitute medical advice or product claims.

By purchasing this product, you acknowledge that you are a qualified researcher and agree to use it in full compliance with all applicable laws and regulations.